Janux Therapeutics, Inc. (JANX) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Win; EPS growth Win.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Win.
- 2025-Q3: Total return Lose; Revenue growth Lose; EPS growth Win.
28/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 6 wins, 6 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
LoseJANX / S&P 10.50% / 15.20% |
WinJANX / S&P 5366.97% / 15.00% |
LoseJANX / S&P -8.38% / 50.40% |
| 2026-Q13/3 |
WinJANX / S&P 0.72% / -4.33% |
WinJANX / S&P 47.10% / 11.30% |
WinJANX / S&P 36.30% / 27.70% |
| 2025-Q41/3 |
LoseJANX / S&P -43.54% / 2.65% |
LoseJANX / S&P -5.55% / 9.00% |
WinJANX / S&P 44.09% / 13.40% |
| 2025-Q31/3 |
LoseJANX / S&P 5.80% / 8.12% |
LoseJANX / S&P -23.37% / 4.61% |
WinJANX / S&P 43.97% / 13.45% |
| 2025-Q21/3 |
LoseJANX / S&P -14.44% / 10.94% |
LoseJANX / S&P -97.10% / 4.83% |
WinJANX / S&P 98.89% / 10.63% |
| 2025-Q12/3 |
LoseJANX / S&P -49.57% / -4.27% |
WinJANX / S&P 28.12% / 4.98% |
WinJANX / S&P 11.57% / 10.57% |
| 2024-Q42/3 |
WinJANX / S&P 17.85% / 2.41% |
WinJANX / S&P 30.99% / 5.25% |
LoseJANX / S&P -4.51% / 6.15% |
| 2024-Q32/3 |
WinJANX / S&P 8.45% / 5.89% |
WinJANX / S&P 54.12% / 5.89% |
LoseJANX / S&P -21.62% / 6.11% |
| 2024-Q22/3 |
WinJANX / S&P 11.26% / 4.28% |
WinJANX / S&P 94.86% / 5.38% |
LoseJANX / S&P -44.79% / 5.12% |
| 2024-Q11/3 |
WinJANX / S&P 250.89% / 10.56% |
LoseJANX / S&P -19.67% / 5.71% |
LoseJANX / S&P -25.31% / 5.59% |
| 2023-Q40/3 |
LoseJANX / S&P 6.45% / 11.69% |
LoseJANX / S&P -6.14% / 6.81% |
LoseJANX / S&P -12.50% / 7.78% |
| 2023-Q32/3 |
LoseJANX / S&P -15.08% / -3.27% |
WinJANX / S&P 14.68% / 7.52% |
WinJANX / S&P 4.23% / -5.03% |
| 2023-Q22/3 |
LoseJANX / S&P -1.90% / 8.74% |
WinJANX / S&P 15.37% / 9.50% |
WinJANX / S&P 27.34% / -8.57% |
| 2023-Q12/3 |
LoseJANX / S&P -8.12% / 7.50% |
WinJANX / S&P 87.19% / 10.77% |
WinJANX / S&P 8.72% / -15.69% |
| 2022-Q41/3 |
LoseJANX / S&P -2.73% / 7.56% |
WinJANX / S&P 136.79% / 11.88% |
LoseJANX / S&P JANX unavailable / -17.99% |
| 2022-Q32/3 |
WinJANX / S&P 10.89% / -4.88% |
WinJANX / S&P 265.31% / 13.47% |
LoseJANX / S&P JANX unavailable / -1.41% |
| 2022-Q22/3 |
WinJANX / S&P -14.85% / -16.10% |
WinJANX / S&P 680.63% / 13.71% |
LoseJANX / S&P JANX unavailable / 11.04% |
| 2022-Q11/3 |
LoseJANX / S&P -27.32% / -4.60% |
WinJANX / S&P 1175.26% / 15.97% |
LoseJANX / S&P JANX unavailable / 42.23% |
| 2021-Q40/3 |
LoseJANX / S&P -8.78% / 11.03% |
LoseJANX / S&P JANX unavailable / 15.00% |
LoseJANX / S&P JANX unavailable / 96.40% |
| 2021-Q30/3 |
LoseJANX / S&P -13.31% / 0.58% |
LoseJANX / S&P JANX unavailable / 10.77% |
LoseJANX / S&P JANX unavailable / 69.42% |
| 2021-Q20/3 |
LoseJANX / S&P JANX unavailable / 8.55% |
LoseJANX / S&P JANX unavailable / 6.58% |
LoseJANX / S&P JANX unavailable / 51.81% |
| 2021-Q10/3 |
LoseJANX / S&P JANX unavailable / 6.17% |
LoseJANX / S&P JANX unavailable / -1.06% |
LoseJANX / S&P JANX unavailable / 7.39% |
| 2020-Q40/3 |
LoseJANX / S&P JANX unavailable / 12.15% |
LoseJANX / S&P JANX unavailable / -3.72% |
LoseJANX / S&P JANX unavailable / -33.42% |
| 2020-Q30/3 |
LoseJANX / S&P JANX unavailable / 8.93% |
LoseJANX / S&P JANX unavailable / -2.04% |
LoseJANX / S&P JANX unavailable / -27.10% |
| 2020-Q20/3 |
LoseJANX / S&P JANX unavailable / 20.54% |
LoseJANX / S&P JANX unavailable / -0.46% |
LoseJANX / S&P JANX unavailable / -27.11% |
| 2020-Q10/3 |
LoseJANX / S&P JANX unavailable / -19.60% |
LoseJANX / S&P JANX unavailable / 3.47% |
LoseJANX / S&P JANX unavailable / -14.75% |
| 2019-Q40/3 |
LoseJANX / S&P JANX unavailable / 9.07% |
LoseJANX / S&P JANX unavailable / 5.36% |
LoseJANX / S&P JANX unavailable / 2.99% |
| 2019-Q30/3 |
LoseJANX / S&P JANX unavailable / 1.70% |
LoseJANX / S&P JANX unavailable / 5.02% |
LoseJANX / S&P JANX unavailable / 0.21% |
| 2019-Q20/3 |
LoseJANX / S&P JANX unavailable / 4.30% |
LoseJANX / S&P JANX unavailable / 6.64% |
LoseJANX / S&P JANX unavailable / 8.65% |
| 2019-Q10/3 |
LoseJANX / S&P JANX unavailable / 13.65% |
LoseJANX / S&P JANX unavailable / 8.12% |
LoseJANX / S&P JANX unavailable / 14.29% |
| 2018-Q40/3 |
LoseJANX / S&P JANX unavailable / -13.52% |
LoseJANX / S&P JANX unavailable / 9.05% |
LoseJANX / S&P JANX unavailable / 18.23% |
| 2018-Q30/3 |
LoseJANX / S&P JANX unavailable / 7.71% |
LoseJANX / S&P JANX unavailable / 10.21% |
LoseJANX / S&P JANX unavailable / 19.06% |
| 2018-Q20/3 |
LoseJANX / S&P JANX unavailable / 3.43% |
LoseJANX / S&P JANX unavailable / 9.03% |
LoseJANX / S&P JANX unavailable / 14.46% |
| 2018-Q10/3 |
LoseJANX / S&P JANX unavailable / -0.76% |
LoseJANX / S&P JANX unavailable / 7.68% |
LoseJANX / S&P JANX unavailable / 12.46% |
| 2017-Q40/3 |
LoseJANX / S&P JANX unavailable / 6.64% |
LoseJANX / S&P JANX unavailable / 7.03% |
LoseJANX / S&P JANX unavailable / 13.82% |
| 2017-Q30/3 |
LoseJANX / S&P JANX unavailable / 4.48% |
LoseJANX / S&P JANX unavailable / 5.68% |
LoseJANX / S&P JANX unavailable / 17.57% |
| 2017-Q20/3 |
LoseJANX / S&P JANX unavailable / 3.09% |
LoseJANX / S&P JANX unavailable / 4.83% |
LoseJANX / S&P JANX unavailable / 17.74% |
| 2017-Q10/3 |
LoseJANX / S&P JANX unavailable / 6.07% |
LoseJANX / S&P JANX unavailable / 3.67% |
LoseJANX / S&P JANX unavailable / 13.32% |
| 2016-Q40/3 |
LoseJANX / S&P JANX unavailable / 3.82% |
LoseJANX / S&P JANX unavailable / 2.09% |
LoseJANX / S&P JANX unavailable / 7.05% |
| 2016-Q30/3 |
LoseJANX / S&P JANX unavailable / 3.85% |
LoseJANX / S&P JANX unavailable / 0.20% |
LoseJANX / S&P JANX unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | JANX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -17.34% | 20.78% |
| Annualized return | -17.34% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | JANX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -41.22% | 83.14% |
| Annualized return | -10.08% | 12.86% |
10Y · 2021-06-11 to 2026-08-27
| Metric | JANX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -25.33% | 319.30% |
| Annualized return | -2.88% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |